Neurelis (United States)

Final results from a Phase 3, long‐term, open‐label, repeat‐dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy

James W. Wheless, Ian Miller, R. Edward Hogan et al. · Epilepsia · 2021 · 65 citations · Full text

Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers

R. Edward Hogan, Barry E. Gidal, Barry Koplowitz et al. · Epilepsia · 2020 · 64 citations · Full text

Pharmacokinetics and safety of VALTOCO (NRL‐1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri‐ictal) and nonseizure (interictal) conditions: A phase 1, open‐label study

R. Edward Hogan, Daniel Tarquinio, Michael R. Sperling et al. · Epilepsia · 2020 · 50 citations · Full text

Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters

James C. Cloyd, Sheryl R. Haut, Enrique Carrazana et al. · Epilepsia · 2021 · 50 citations · Full text

Drug Safety, Neurophysiology, Psychotropic Medication +13

Examining the patient and caregiver experience with diazepam nasal spray for seizure clusters: Results from an exit survey of a phase 3, open-label, repeat-dose safety study

Patricia Penovich, James W. Wheless, R. Edward Hogan et al. · Epilepsy & Behavior · 2021 · 48 citations · Full text